J. Frenel

发表

Association between post-operative hPG80 (circulating progastrin) detectable level and worse prognosis in glioblastoma

M. Aumont, L. Doucet, A. Cailleteau, 2023, ESMO Open.

Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials.

K. Hoang-Xuan, M. Sanson, A. Idbaih, 2022, European journal of cancer.

Clinical Insights: Neoadjuvant Therapy in Breast Cancer

M. Campone, J. Frenel, 2014 .

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience

M. Campone, C. Leux, M. Denis, 2013, Journal of Neuro-Oncology.

Lapatinib in Metastatic Breast Cancer

M. Campone, D. Berton‐Rigaud, S. Sadot-Lebouvier, 2009, Women's health.

Clinical Insights: Neoadjuvant Therapy in Breast Cancer

M. Campone, J. Frenel, M. Campone, 2014 .

Challenges in glioblastoma research: focus on the tumor microenvironment.

I. Fournier, F. Ducray, M. Sanson, 2022, Trends in cancer.

Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas

M. Campone, J. Mosnier, C. Sagan, 2008, British Journal of Cancer.

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

A. Vincent-Salomon, J. Lemonnier, J. Canon, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature

C. Linassier, L. Ouldamer, M. Cancel, 2024, The oncologist.

Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype.

P. Jézéquel, W. Gouraud, H. Lasla, 2024, Breast cancer.

First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.

F. Dalenc, T. Bachelot, M. Arnedos, 2023, European journal of cancer.